Patent ID: 6645941
Filing Date: 2003-11-11
Classification: A61P,C07H

Abstract:
A compound of formula I, or a pharmaceutically acceptable salt, ester, or prodrug thereof: wherein,A is i) â€”OH; ii) â€”ORp, where Rp is a hydroxy protecting group; iii) â€”R1, where R1 is aryl, substituted aryl, heteroaryl, or substituted heteroaryl; iv) â€”OR1, where R1 is as previously defined; v) â€”R2, where R2 is (a) hydrogen; (b) halogen; (c) â€”C1--C6 alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S or N, optionally substituted with one or more substituents selected from halogen, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; (d) â€”C2-C6 alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituents selected from halogen, aryl, substituted aryl, hetbroaryl, or substituted heteroaryl; or (e) â€”C2-C6 alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S or N, optionally substituted with one or more substituents selected from halogen, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; vi) â€”OR2, where R2 is previously defined; vii) â€”S(O)nR11, where n=0, 1 or 2, and R11 is R1 or R2, where R1 and R2 are previously defined; viii) â€”NHC(O)R11, where R11 is as previously defined; ix) â€”NHC(O)NHR11, where R11 is as previously defined; x) â€”NHS(O)2R11, where R11 is as previously defined; xi) â€”NR14R15, where R14 and R15 are each independently R11, where R11 is as previously defined; or xii) â€”NHR3, where R3 is an amino protecting group; B is i) hydrogen; ii) deuterium; iii) halogen; iv) â€”OH; v) â€”R1, where R1 is as previously defined; vi) â€”R2, where R2 is as previously defined; or vii) â€”ORp, where Rp is as previously defined, provided that when B is halogen, â€”OH or ORp, A is R1 or R2; or, alternatively, A and B taken together with the carbon atom to which they are attached are i) C&boxH;O; ii) C(OR2)2, where R2 is as previously defined; iii) C(SR2)2, where R2 is as previously defined; iv) C[â€”O(CH2)m]2, where m=2 or 3; v) C[â€”S(CH2)m]2, where m is as previously defined; vi) C&boxH;CHR11, where R11 is as previously defined; vii) C&boxH;Nâ€”Oâ€”R11, where R11 is as previously defined; viii) C&boxH;NNHR11, where R11 is as previously defined; ix) C&boxH;NNHC(O)R11, where R11 is as previously defined; x) C&boxH;NNHC(O)NHR11, where R11 is as previously defined; xi) C&boxH;NNHS(O)2R11, where R11 is as previously defined; xii) C&boxH;NNHR3, where R3 is as previously defined; or xiii)C&boxH;NR11, where R11 is as previously defined; L is i) â€”CH3; ii) â€”CH2CH3; iii) â€”CH(OH)CH3; iv) â€”C1-C6 alkyl, optionally substituted with one or more substituents selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl; v) â€”C2-C6 alkenyl, optionally substituted with one or more substituents selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or vi) â€”C2-C6 alkynyl, optionally substituted with one or more substituents selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl; D is â€”N(Q)CH2â€”, â€”N(Râ€²)C(O)â€”, or â€”N&boxH;C(ORâ€²)â€”, wherein Râ€² is R11 as previously defined and Q is defined herein; Q is i) hydrogen; ii) â€”C1-C12-alkyl, C3-C12-alkenyl, or C3-C12-alkynyl, all optionally substituted with one or more substituents independently selected from: (a) halogen; (b) â€”OR6, wherein R6 is selected from: 1. hydrogen; 2. â€”C1-C12-alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S or N, optionally substituted with one, two, or three substituents independently selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl; 3. aryl; 4. substituted aryl; 5. heteroaryl; and 6. substituted heteroaryl; (c) â€”NR4R5, where R4 and R5 are each independently R6, where R6 is as previously defined; or in the alternative R4 and R5, together with the atom to which they are attached, form a heterocycloalkyl or substituted heterocycloalkyl moiety; (d) &boxH;Nâ€”Oâ€”R6, where R6 is as previously defined; (e) â€”R1, where R1 is as previously defined; (f) â€”C3-C8-cycloalkyl; (g) substituted â€”C3-C8-cycloalkyl; (h) heterocycloalkyl; (i) substituted heterocycloalkyl; (j) â€”NHC(O)R6, where R6 is as previously defined; (k) â€”NHC(O)OR7, where R7 is selected from: 1. â€”C1-C12-alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S or N, optionally substituted with one, two, or three substituents independently selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl; 2. aryl; 3. substituted aryl; 4. heteroaryl; or 5. substituted heteroaryl; (i) â€”NHC(O)NR4R5, where R4 and R5 are as previously defined; (m) â€”OC(O)NR4R5, where R4 and R5 are as previously defined; (n) â€”OC(O)R7, where R7 is as previously defined; (o) â€”OC(O)OR7, where R7 is as previously defined; (p) â€”OC(O)NR4R5, where R4 and R5 are as previously defined; (q) â€”C(O)R6, where R6 is as previously defined; (r) â€”CO2R6, where R6 is as previously defined; or (s) â€”C(O)NR4R5, where R4 and R5 are as previously defined; X is hydrogen; Y is i) hydrogen; ii) â€”OH; iii) â€”ORp, where Rp is as previously defined; iv) â€”OR11, where R11 is as previously defined; v) â€”OC(O)R11, where R11 is as previously defined; vi) â€”OC(O)NHR11, where R11 is as previously defined; vii) â€”S(O)nR11, where n and R11 are as previously defined; viii) â€”where R3â€³ is hydrogen or methyl; R4â€³ is hydrogen or Rp, where Rp is as previously defined; or in the alternative X and Y combined together are oxo; Z is i) hydrogen; ii) methyl; or iii) halogen; and R2â€² is hydrogen or Rp, where Rp, is as previously defined.